Last reviewed · How we verify

NCT06274957

The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation

Recruiting now NA Last updated 30 May 2024
What this trial tests

NA trial testing CONTROL in COPD Exacerbation Acute in 27 participants. Currently enrolling.

Timeline
1 May 2024
Primary endpoint
10 June 2024
17 June 2024

Quick facts

Lead sponsorSaglik Bilimleri Universitesi
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment27
Start date1 May 2024
Primary completion10 June 2024
Estimated completion17 June 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Saglik Bilimleri Universitesi — full company profile →

Who can join

40 and older, any sex, with COPD Exacerbation Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CONTROL

Trials testing the same drug.

Other recruiting trials for COPD Exacerbation Acute

Currently open trials in the same condition.

Other Saglik Bilimleri Universitesi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06274957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing